ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 092,11
-0,61%
Dow Jones
39 671,04
-0,51%
DAX
18 680,20
-0,25%
Brent Oil
81,375
-0,19%
Bitcoin
69 327,99
0,33%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Equillium Inc (EQ)

  7. Equillium Inc (EQ) Actualités

EQ

Equillium (EQ)

Equillium Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:EQ
DateHeureSourceTitreSymboleSociété
14/05/202414h00Business WireEquillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseNASDAQ:EQEquillium Inc
09/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQEquillium Inc
09/05/202422h01Business WireEquillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical HighlightsNASDAQ:EQEquillium Inc
07/05/202414h00Business WireEquillium Announces Poster Presentation at the Annual Meeting of The American Association of ImmunologistsNASDAQ:EQEquillium Inc
03/04/202414h00Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EQEquillium Inc
01/04/202414h00Business WireEquillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus NephritisNASDAQ:EQEquillium Inc
25/03/202421h01Business WireEquillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical HighlightsNASDAQ:EQEquillium Inc
22/03/202413h00Business WireEquillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational ConferenceNASDAQ:EQEquillium Inc
08/03/202423h35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EQEquillium Inc
08/03/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
23/02/202423h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EQEquillium Inc
04/01/202400h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
21/12/202314h00Business WireEquillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac DiseaseNASDAQ:EQEquillium Inc
20/11/202317h23PR Newswire (Canada)EQ Bank Card launches in Québec as Carte Banque EQNASDAQ:EQEquillium Inc
13/11/202315h00Business WireEquillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of RheumatologyNASDAQ:EQEquillium Inc
08/11/202322h01Business WireEquillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:EQEquillium Inc
06/11/202314h00Business WireEquillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of NephrologyNASDAQ:EQEquillium Inc
19/10/202314h00Business WireEquillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of RheumatologyNASDAQ:EQEquillium Inc
16/10/202314h00Business WireEquillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics SymposiumNASDAQ:EQEquillium Inc
03/10/202314h00Business WireEquillium to Host Analyst & Investor DayNASDAQ:EQEquillium Inc
02/10/202314h00Business WireEquillium to Present at the JonesTrading 2023 Healthcare SummitNASDAQ:EQEquillium Inc
20/09/202314h00Business WireEquillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event ConferencesNASDAQ:EQEquillium Inc
30/08/202314h00Business WireEquillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor ConferenceNASDAQ:EQEquillium Inc
09/08/202322h01Business WireEquillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:EQEquillium Inc
02/08/202322h00Business WireEquillium Announces $7.5 Million Share Repurchase ProgramNASDAQ:EQEquillium Inc
01/06/202314h00Business WireEquillium to Present at the Jefferies Global Healthcare & LD Micro Invitational ConferencesNASDAQ:EQEquillium Inc
25/05/202322h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EQEquillium Inc
24/05/202300h15Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:EQEquillium Inc
11/05/202322h01Business WireEquillium Reports First Quarter 2023 Financial Results and Provides Clinical UpdatesNASDAQ:EQEquillium Inc
24/04/202314h00Business WireEquillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow TransplantationNASDAQ:EQEquillium Inc
 Showing the most relevant articles for your search:NASDAQ:EQ

Dernières Valeurs Consultées

BIT
P1ZJ51
NLBNPIT1ZJ51 20240918 17...
EU
H826S
H826S
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés